2024 Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages Read more
2024 Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products Read more
2024 Improving Equity in Oncology Clinical Trials: Challenges and Strategies for Setting Diversity Enrollment Goals View PDF
2023 An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022 Read more
2023 Interpreting Data from Dose-Finding Studies in Early Phase Oncology Trials to Determine the Optimal Dose View PDF
2023 Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials View PDF
Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials View PDF